Status:
COMPLETED
Buprenorphine Induction and Naloxone Distribution Program-Combined With Warm Hand-Off Referral to Continued Treatment
Lead Sponsor:
Jerry Cochran
Conditions:
Opioid Abuse
Eligibility:
All Genders
18+ years
Brief Summary
This study is a collaboration between the University of Utah and Castleview Hospital in Price, Utah. Buprenorphine is a medication approved by the FDA to treat Opioid Use Disorder (OUD). Castleview H...
Detailed Description
Among health care environments, ED often are the front lines of care for those with OUD or who experience opioid overdose. The University of Utah Hospital ED has the Bridge Program which provides bup...
Eligibility Criteria
Inclusion
- For qualitative interviews with providers, administrators, stakeholders:
- Must be affiliated with Castleview Hospital as a provider, administrator or stakeholder.
- For the quantitative surveys:
- Must be a Castleview Hospital patient who receives the BINDeR-Tx model.
Exclusion
- For qualitative interviews with providers, administrators, stakeholders:
- Not familiar with the BINDeR-Tx model
- No interaction with the BINDeR-Tx model
- For the quantitative surveys:
- Unable to speak and read English
- Subject is unable to provide contact information
Key Trial Info
Start Date :
April 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2024
Estimated Enrollment :
65 Patients enrolled
Trial Details
Trial ID
NCT06087991
Start Date
April 1 2023
End Date
October 1 2024
Last Update
June 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Utah
Salt Lake City, Utah, United States, 84108